Clinical trial · Interventional
Al18F-HER2-BCH PET in Breast Patients Treated With ADC Therapy
Al18F-HER2-BCH PET/CT to Predict Response in Breast Patients Treated With ADC Therapy
NCT06909604CI-TRIAL-00111444FHERADrecruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To use the molecular PET radionuclide (F-18) labelled HER2 Affibody to evaluate the predictive and prognostic value in breast patients treated with ADC therapy
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| HER2 expression of PET imaging | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- HER2 expression of PET imaging
- description
- Evaluate the predict potential of HER2 imaging using 18F-labelled HER2 affibody , evaluate the predictive and prognostic value of HER2 PET imaging in breast cancer patients treated with ADC therapy
- interventionNames
- Radiation: HER2 expression of PET imaging
Primary outcomes (1)
- measure
- Changes in SUVmax before and after treatment
- timeFrame
- Before treatment, 9 weeks after treatment, before surgery
- description
- The uptake of the tracer in the primary and metastatic tumor lesions by measuring standardized uptake value (SUV) on PET/CT
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Aged ≥18 years old; ECOG 0 or 1; 2. Patients with HER2 positive or low tumors; 3. Receives neoadjuvant therapy 4. Has adequate cardiac, bone marrow, renal, hepatic and blood clotting functions; 5. Life expectancy \> 3 months - Exclusion Criteria: 1. Significant hepatic or renal dysfunction; 2. Is pregnant or ready to pregnant; 3. Cannot keep their states for half an hour; 4. Refused to join the clinical research; 5. Suffering from claustrophobia or other mental disorders; 6. Any other situation that researchers considered it unsuitable to participate in the trial.
References
Publications (0)
Data not yet available
No reference posted for this study.